AN2 Therapeutics, Inc. ANTX
4.88
(0.01)
(0.20%)
as of 25 Sep
- Market cap
- $184.5M
- P/E
- 0.0×
Follow ANTX
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
9.33 | 6.87 | 15.73 | 14.32 |
Net Debt/EBITDA |
6.04 | 6.15 | 8.02 | 8.71 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.68 | 0.60 | 1.20 | 0.86 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.21) | (0.17) | (0.35) | (0.16) | |
Cash per Share |
2.05 | 1.92 | 2.50 | 1.75 | |
Shareholders Equity per Share |
1.99 | 1.76 | 2.40 | 1.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.99 | 1.76 | 2.40 | 1.70 | |
Free Cash Flow |
(6.37) | (5.24) | (12.07) | (7.00) | |
Working Capital |
57.16 | 51.22 | 81.93 | 74.41 | |
Net Current Asset Value |
57.16 | 51.05 | 81.76 | 74.24 | |
| Other line items | |||||
Quick Ratio |
9.03 | 6.65 | 15.33 | 14.04 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.21) | (0.17) | (0.35) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.97 | 3.17 | 2.84 | 2.04 | |
Average Assets |
82.46 | 77.02 | 84.42 | 78.75 | |
Average Common Equity |
74.02 | 67.45 | 77.54 | 72.38 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates